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Introduction
The heart responds to chronic stresses such as hemodynamic overload through hypertrophic remodeling 
(i.e., ventricular hypertrophy), which initially maintains normal contractile function but, when protract-
ed, progresses to heart failure (1). Pathological left ventricular hypertrophy (LVH) is characterized by a 
broad range of  structural and functional perturbations including cardiomyocyte hypertrophy, abnormal 
excitation-contraction coupling, contractile dysfunction, altered myocyte viability, interstitial fibrosis, and 
arrhythmia. A prominent feature of  LVH is an alteration in cardiac energy substrate utilization. Whereas 
the healthy adult heart relies predominantly on fatty acid oxidation for energy generation, there is a switch 
in substrate preference from fatty acids to carbohydrates in diverse animal models of  LVH and heart failure 
(2–4). It is suggested that this switch away from fatty acid oxidation may be adaptive by increasing cardiac 
efficiency in terms of  oxygen consumption, since glucose oxidation has a lower oxygen requirement than 
fatty acid oxidation. In line with this idea, therapeutic approaches that inhibit fatty acid oxidation and/or 
promote an increase in glucose utilization are currently being assessed in patients with chronic heart failure 
(4, 5). However, the exact relationship between changes in energy substrate utilization and the functional 
state of  the hypertrophied heart or its propensity to develop heart failure remains unclear. Moreover, the 
mechanisms underlying these changes in energy metabolism are incompletely understood.
The complex changes in gene and protein expression and function that drive hypertrophic cardiac remod-
eling are directed by intracellular signaling pathways, which are activated in response to hemodynamic and 
other stresses (6, 7). A well-established paradigm in the field is that adaptive remodeling may be driven by 
Cardiac hypertrophic remodeling during chronic hemodynamic stress is associated with a switch 
in preferred energy substrate from fatty acids to glucose, usually considered to be energetically 
favorable. The mechanistic interrelationship between altered energy metabolism, remodeling, 
and function remains unclear. The ROS-generating NADPH oxidase-4 (Nox4) is upregulated in the 
overloaded heart, where it ameliorates adverse remodeling. Here, we show that Nox4 redirects 
glucose metabolism away from oxidation but increases fatty acid oxidation, thereby maintaining 
cardiac energetics during acute or chronic stresses. The changes in glucose and fatty acid 
metabolism are interlinked via a Nox4-ATF4–dependent increase in the hexosamine biosynthetic 
pathway, which mediates the attachment of O-linked N-acetylglucosamine (O-GlcNAcylation) to 
the fatty acid transporter CD36 and enhances fatty acid utilization. These data uncover a potentially 
novel redox pathway that regulates protein O-GlcNAcylation and reprograms cardiac substrate 
metabolism to favorably modify adaptation to chronic stress. Our results also suggest that 
increased fatty acid oxidation in the chronically stressed heart may be beneficial.
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molecular signaling pathways that are distinct from those that drive maladaptive remodeling. In this regard, 
redox-regulated signaling mediated by NADPH oxidase (Nox) family proteins is of  particular interest (8). 
These membrane-associated enzymes generate ROS by catalyzing electron transfer from NADPH to molecu-
lar oxygen and are involved in localized redox signaling during processes such as cell proliferation, migration, 
differentiation, and tissue repair (9, 10). Of the 7 mammalian Nox isoforms (Nox1–5 and Duox1–2), Nox2 
and Nox4 are expressed in the heart, and previous work from our laboratory and others identified distinct 
roles for these isoforms in the cardiac adaptation to stress conditions (9, 11). Nox2-mediated signaling pro-
motes several detrimental processes in the pathologically remodeling heart, including cardiomyocyte hyper-
trophy, contractile dysfunction, arrhythmia, interstitial fibrosis, cell death, and cardiac rupture after myocar-
dial infarction (11, 12). In contrast, gain- and loss-of-function approaches in mouse models showed that the 
upregulation of  Nox4 during chronic hemodynamic or ischemic stress can mediate protective effects (13, 14). 
In the setting of  chronic hemodynamic overload, Nox4 promoted adaptive cardiac remodeling, with less LVH 
and better preserved function (13). While a number of  signaling pathways modulated by Nox4 that may pro-
tect the heart have been identified (13, 15, 16), the precise changes induced in the remodeling heart to promote 
compensated cardiac function remain incompletely understood.
To elucidate processes that mediate Nox4-dependent protection against pressure overload–induced 
adverse cardiac remodeling, we initially pursued a proteomics approach in which normal mouse hearts 
were compared with hearts from mice with cardiomyocyte-targeted Nox4 overexpression or cardio-
myocyte-targeted Nox2 overexpression, with and without chronic hemodynamic stress. This revealed 
significant perturbations in metabolic pathways in the Nox4-modulated cardiac proteome as com-
pared with the other groups. Subsequent detailed analyses revealed that Nox4 induces a substantial 
reprogramming of  glucose and fatty acid metabolism. We find that Nox4 induces a marked increase 
in activity of  the hexosamine biosynthetic pathway (HBP), a branch pathway of  glycolysis that drives 
enhanced protein O-linked glycosylation with N-acetylglucosamine (O-GlcNAcylation), whereas 
there is a reduction in glucose oxidation through the TCA cycle. In parallel, fatty acid oxidation is 
significantly increased, such that the hearts maintain a well-compensated energetic status in response 
to chronic hemodynamic or acute neurohumoral stresses. Mechanistically, the Nox4-induced augmen-
tation of  HBP activity is mediated by the transcription factor ATF4, with the increase in fatty acid 
oxidation related at least in part to an increased O-GlcNAcylation of  the fatty acid transporter CD36. 
Collectively, these findings uncover a Nox4-regulated pathway that drives interlinked and complemen-
tary changes in cardiac glucose and fatty acid utilization. This reprogramming of  cardiac metabolism, 
which fully maintains energetic status, may be fundamental to the protective effects of  Nox4 during 
chronic hemodynamic stress.
Results
Nox4 modulates the metabolic proteome of  the mouse heart. To obtain an overview of  potential adaptive path-
ways triggered by Nox4, we first undertook a proteomic analysis by difference in-gel electrophoresis 
(DIGE) of  hearts isolated from Nox4 TG mice and their WT littermates, both under unstressed conditions 
and in the early stages after induction of  pressure overload. Nox4 TG mice were reported previously to 
have a modest increase in Nox4 levels and oxidase activity, comparable with the increase in Nox4 observed 
after chronic pressure overload in WT mice (13) (Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.96184DS1). They exhibited significantly less 
cardiac hypertrophy and better contractile function than WT littermates at 3 weeks after abdominal aortic 
banding (Supplemental Figure 1A). To control for potential nonspecific effects related to ROS production, 
we also studied the proteome profile of  Nox2-overexpressing hearts (17) under similar conditions, therefore 
enabling isoform-specific pathways to be assessed.
A principal components analysis revealed that Nox4 TG hearts had a distinct proteome profile 
as compared with either WT or Nox2-overexpressing hearts, both under unstressed and stressed con-
ditions (Supplemental Figure 1B). Unstressed Nox4 TG hearts had 97 significantly upregulated and 
64 significantly downregulated protein spots as compared with WT littermates (Supplemental Figure 
1C). Following protein identification by mass spectrometry (MS) and categorization according to gene 
ontology (www.geneontology.org), it was evident that Nox4 altered the expression level of  many pro-
tein classes pertinent to heart failure pathobiology (Figure 1A). Of  note, the category with the highest 
number of  differentially expressed proteins was “metabolism.” Using Reactome analysis, among the 
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most overrepresented pathways in Nox4 TG hearts were those involved in glucose and fatty acid metab-
olism (Table 1), with both up- and downregulation of  different glycolytic proteins and a general down-
regulation of  proteins involved in β-oxidation (Supplemental Figure 1D). Similar changes were also 
observed in the comparison of  pressure-overloaded Nox4 TG versus WT hearts (Supplemental Figure 
1D). We confirmed the pattern of  changes in protein abundance in Nox4 TG hearts by IB (Figure 1B). 
The quantification of  mRNA expression levels of  these proteins revealed a similar pattern of  change for 
most but not all transcripts (Figure 1C). Notably, most of  the proteins involved in β-oxidation were not 
significantly altered at transcript level, apart from Acaa2. These findings suggest that glucose and fatty 
acid metabolism may be significantly perturbed by an increase in cardiomyocyte Nox4 levels.
Nox4-overexpressing hearts exhibit altered substrate utilization. To ascertain the overall impact of  the above 
changes on glucose and/or fatty acid utilization, we next performed ex vivo working heart perfusion stud-
ies with radiolabeled substrates to estimate glucose uptake, glycolysis, glucose oxidation, and fatty acid 
oxidation rates (18). Unstressed Nox4 TG hearts showed a significant decrease in glucose oxidation rate as 
compared with WT hearts. Glycolysis, as assessed by the production of  3H2O predominantly at the step cat-
alyzed by enolase, also tended to be lower in Nox4 TG hearts (Figure 2, A and B), while the glucose uptake 
rate was unaltered (Figure 2C). In parallel, there was a profound increase in the fatty acid oxidation rate in 
Nox4 TG hearts (Figure 2D). Similar findings were observed in hypertrophied Nox4 TG hearts compared 
with hypertrophied WT controls (Figure 2, A–D).
Figure 1. Nox4 alters the levels of cardiac proteins involved in glycolysis and fatty acid oxidation. (A) Categorization of differentially expressed pro-
teins in Nox4 TG hearts by biological function, according to gene ontology. Difference in-gel electrophoresis (DIGE) was used to determine differentially 
expressed protein spots from WT and Nox4 TG hearts, followed by mass spectrometry to identify the proteins. (B) Immunoblotting for proteins involved in 
glycolysis and fatty acid β-oxidation. Representative immunoblots are shown to the left. Relative change in levels compared with WT hearts are shown to 
the right. *P < 0.05, 2-tailed t test (n = 3–4). See Supplemental Figure 1C for full names of the proteins. (C) mRNA expression levels of the proteins shown 
in C, expressed as fold-change compared with WT. *P < 0.05, 2-tailed t test (n = 3–6 per group).
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There was no difference in insulin sensitivity between Nox4 TG and WT hearts, as assessed by an 
insulin-induced increase in myocardial Akt phosphorylation at Ser473 (Figure 2E and Supplemental Figure 
2A). The increase in fatty acid oxidation in Nox4 TG hearts could, in principle, lead to an increased phos-
phorylation and inhibition of  pyruvate dehydrogenase (PDH), thereby limiting the entry of  glucose-derived 
pyruvate into the TCA cycle and reducing the glucose oxidation rate. However, we found no differences 
in PDH phosphorylation or activity between Nox4 TG and WT hearts (Figure 2F and Supplemental Fig-
ure 2B). We also assessed whether the changes in substrate utilization might be driven by alterations at 
the mitochondrial level. Mitochondria were isolated from Nox4 TG and WT hearts, and the respiration 
rates for different substrates were compared (Figure 2G). There was no difference in O2 consumption rate 
between genotypes with palmitoylcarnitine as a substrate, while the rate was slightly higher in the Nox4 TG 
group in the presence of  pyruvate. These results indicate that the mitochondrial capacity for respiration is 
unaltered in Nox4 TG hearts and that the reduced rate of  glucose oxidation and increased rate of  fatty acid 
oxidation most likely occur independently of  changes in mitochondrial metabolic capacity.
Nox4 promotes an increase in proximal glycolytic metabolites and diversion into the HBP. The decrease in gly-
colysis and glucose oxidation in the absence of  reduced glucose uptake in Nox4 TG hearts raised the pos-
sibility that the normal metabolism of  glucose via a series of  glycolytic reactions to pyruvate is perturbed. 
We therefore undertook targeted metabolomics by MS to quantify the levels of  glycolytic intermediates in 
Nox4 TG and WT hearts. This analysis revealed that there was a relative increase in the steady-state pool 
of  proximal glycolytic metabolites in unstressed Nox4 TG compared with WT hearts, and it was even more 
marked in hearts from animals that had undergone aortic banding (Figure 3A).
We surmised that the altered balance between proximal and distal glycolytic metabolites in Nox4 TG 
hearts might reflect increased diversion into branch pathways. One such pathway is the HBP, which metab-
olises fructose 6-phosphate to uridine diphosphate–N-acetylglucosamine (UDP-GlcNAc) (Figure 3B) and 
is known to be activated during the cardiac stress response to pressure overload (19). UDP-GlcNAc is uti-
lized as the substrate for the posttranslational O-linked glycosylation (O-GlcNAcylation) of  a wide variety 
of  proteins whereby a single N-acetylglucosamine (O-GlcNAc) moiety is attached to serine and threonine 
residues by the enzyme O-GlcNAc transferase (Ogt) (20). Using an antibody that detects O-GlcNAc mod-
ifications, we found that overall protein O-GlcNAcylation was significantly increased in Nox4 TG hearts 
compared with WT, both under unstressed conditions and after chronic pressure overload (Figure 3C). 
These results indicate that Nox4 promotes a relative increase in glucose diversion into the HBP rather than 
the main pathway of  glycolysis to pyruvate.
Nox4 modulates fatty acid oxidation via the HBP. To gain further insight into the relationship between 
Nox4 and altered substrate utilization, we turned to a cultured cardiomyocyte system in which either 
endogenous Nox4 was knocked down by infecting cells with an adenoviral vector expressing a specific 
shRNA or Nox4 levels were increased by infection with a Nox4 adenovirus (Supplemental Figure 3A). 
We studied the oxidation of  different substrates with the use of  an extracellular flux analyzer. The over-
expression of  Nox4 significantly increased the maximal respiration rate for palmitate, an effect that was 
abolished in the presence of  catalase (Figure 4A and Supplemental Figure 3B). In contrast, the knock-
down of  endogenous Nox4 significantly decreased the maximal palmitate respiration rate (Figure 4B). 
Turning to glucose, the knockdown of  Nox4 significantly increased the basal oxidation rate, whereas its 
overexpression had no significant effect (Figure 4, C and D). In parallel, glycolysis — as assessed by the 
extracellular acidification rate (ECAR) — was significantly increased by the knockdown of  Nox4, while 
Table 1. Top enriched pathways from identified proteins using Reactome database pathway analysis
Pathway name Identified proteins
Glycolysis KPYM;ENOB;TPIS;PGAM1;ALDOA
Mitochondrial fatty acid β-oxidation ACADM;DECR;HCDH
Metabolism of polyamines PSA3;KCRM;PSA5;PSA6;KCRS
Creatine metabolism KCRM;KCRS
Regulation of mRNA stability PSA3;1433B;HSP7C;PSA5;PSA6;HSPB1
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Figure 2. Myocardial substrate utilization in isolated Nox4 TG and WT hearts. (A–D) The schematics at the top show the tracers and readouts that 
were used. (A) Glucose oxidation rate (n = 6–14 per group); (B) glycolytic rate (n = 6–9 per group); (C) glucose uptake rate (n = 3–14 per group); and (D) 
palmitate oxidation rate (n = 4–8 per group). *P < 0.05, **P < 0.01, ****P < 0.0001, 2-way ANOVA with Tukey’s post hoc correction. (E) Myocardial 
insulin sensitivity assessed as the increase in Akt phosphorylation in response to i.p. insulin (0.75 IU/kg). The level of phosphorylated Akt is normal-
ized by total Akt levels.***P < 0.001, ****P < 0.0001, 2-way ANOVA with Tukey’s post hoc correction (n = 3–4 per group). (F) Levels of phosphorylat-
ed pyruvate dehydrogenase (P-Pdha E1α) (left) and PDH activity (right) in mitochondrial fractions from WT and Nox4 TG hearts; 2-tailed t test, n = 
4 per group. (G) Respiration with palmitoylcarnitine or pyruvate as substrates in mitochondria isolated from Nox4 TG and WT hearts. Leak denotes 
respiration measured in the presence of substrates and without ADP. Ox Phos denotes oxidative phosphorylation following the addition of ADP. 
Leako denotes respiration rates after addition of oligomycin. *P < 0.05, 2-tailed t test, n = 6 per group.
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overexpression of  Nox4 had no effect (Supplemental Figure 3C). The oxidation rate for pyruvate was 
unaffected either by knockdown or overexpression of  Nox4 (Figure 4, E and F), consistent with a lack of  
effect on mitochondrial function per se. Overall, these results are similar to the findings in whole hearts.
We further assessed potential mechanisms underlying the Nox4-dependent increase in fatty acid 
oxidation rate. There were no changes in the expression levels of  carnitine palmitoyl transferase 1 and 
2 (Cpt1b and Cpt2), which are required for the transport of  long-chain fatty acids into mitochondria 
and their subsequent oxidation (Supplemental Figure 4A). In addition, the levels of  malonyl CoA, an 
important allosteric regulator of  fatty acid oxidation, were similar in WT and Nox4 TG hearts (Sup-
plemental Figure 4B). The overexpression of  Nox4 in cultured cardiomyocytes resulted in a marked 
increase in O-GlcNAcylated proteins (Figure 5A), similar to the results in Nox4 TG hearts. Since pre-
vious studies have linked cardiac O-GlcNAcylation to increases in fatty acid oxidation (21, 22), we 
tested whether the Nox4-induced increases in O-GlcNAcylation and fatty acid oxidation were caus-
atively linked. Protein O-GlcNAcylation was inhibited in Nox4-overexpressing cardiomyocytes using 
Ac-5SGlcNAc, a specific competitive inhibitor of  Ogt (23) (Supplemental Figure 4C). We observed that 
Figure 3. Nox4 enhances protein O-GlcNAcylation via the hexosamine biosynthetic pathway. (A) Glycolytic intermediates in Nox4 TG and WT hearts, 
quantified by LC-MS. Data are expressed as fold-change relative to WT. *P < 0.05, 2-tailed t test, n = 6. Schematic to the left shows the pathway for conver-
sion of glucose 6-phosphate (G6P) to pyruvate (PYR). F6P, fructose 6-phosphate; FBP, fructose 1.6-bisphosphate; DHAP, dihydroxyacetone phosphate; BPG, 
1,3-bisphosphoglycerate; 2,3PG, 3-phosphoglycerate and 2-phosphoglycerate; PEP, phosphoenolpyruvate. (B) Schematic of the hexosamine biosynthesis 
pathway (orange arrows), which branches off at F6P. Gfat, glutamine fructose-6-phosphate aminotransferase; Ogt, O-GlcNAc transferase. (C) Immunoblot-
ting for O-GlcNAc–modified proteins in hearts of WT and Nox4 TG mice. Representative blots are shown to the left, and mean data are shown to the right. 
Coomassie staining of gels was used to confirm equal protein loading. ****P < 0.0001, 2-way ANOVA with Tukey’s post hoc correction; n = 3 per group.
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the increase in fatty acid oxidation induced by Nox4 overexpression was abolished in the presence of  
the O-GlcNAcylation inhibitor (Figure 5B). Conversely, we could partially rescue fatty acid oxidation 
in Nox4-knockdown cardiomyocytes by augmenting HBP activity with N-acetyl-D-glucosamine supple-
mentation (Figure 5C).
The augmentation of  fatty acid oxidation by O-GlcNAcylation has been suggested to involve the 
modification of  the fatty acid transporter CD36, which is a key regulator of  myocardial fatty acid 
uptake (21). We found that overexpression of  Nox4 in cultured cardiomyocytes was accompanied by 
substantially increased O-GlcNAcylation of  CD36, as assessed by IP studies, along with a smaller 
increase in total CD36 levels (Figure 5D and Supplemental Figure 4D). Conversely, the knockdown 
of  Nox4 resulted in a significant decrease in CD36 O-GlcNAcylation and total CD36 levels (Figure 
5E). When cells in which Nox4 had been depleted were treated with N-acetyl-D-glucosamine to aug-
ment HBP activity, the reduction in CD36 O-GlcNAcylation and total CD36 levels was reversed (Fig-
ure 5E). A similar increase in O-GlcNAcylation of  CD36 and total CD36 levels to that observed in 
Figure 4. Nox4 increases fatty acid oxida-
tion in cultured cardiomyocytes. (A, C, and 
E) Effect of adenoviral-mediated overex-
pression of Nox4 (Ad.Nox4) or a control 
β-galactosidase protein (Ad.β-Gal) on the 
oxygen consumption rate (OCR) in the 
presence of (A) palmitate, (C) glucose, or (E) 
pyruvate as substrate. (B, D, and F) Effect of 
shRNA-mediated knockdown of Nox4 (Ad.
shNox4) or control (Ad.Ctl) on the OCR in the 
presence of (B) palmitate, (D) glucose, or (F) 
pyruvate as substrate. OCR was measured 
in an extracellular flux analyzer under basal 
conditions (Basal) and after the addition of 
FCCP (p-trifluoromethoxy carbonyl cyanide 
phenyl hydrazine) to induce maximal respi-
ration (Maximal). *P < 0.05, **P < 0.01, ***P 
< 0.001, 2-way ANOVA with Sidak’s post hoc 
correction; n = 9 per group. See also Supple-
mental Figure 3.
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Figure 5. Nox4 modulates fatty acid oxidation via protein O-GlcNAcylation. (A) Nox4 overexpression increased protein O-GlcNAcylation in 
cultured cardiomyocytes. Tubulin was used as a loading control. (B) Inhibition of protein O-GlcNAcylation with an HBP inhibitor (Ac-5SGlcNAc, 50 
μM) reversed the effect of Nox4 overexpression on oxygen consumption rate (OCR) for palmitate in cardiomyocytes. *P < 0.05, 2-tailed t test, n = 
9. (C) In cardiomyocytes in which Nox4 was knocked down, supplementation with GlcNAc (40mM) partially increased the OCR for palmitate. *P < 
0.05, 2-tailed t test, n = 12. (D) IP of CD36 in protein lysates (membrane fractions) from cardiomyocytes overexpressing Nox4 or β-Gal control was 
followed by IB for CD36 and for O-GlcNAcylation (O-GlcNAc). A representative immunoblot is shown to the left. To the right are mean data from 4 
independent experiments. **P < 0.01, ***P < 0.001, 2-tailed t test. (E) IP of CD36 followed by IB for CD36 and O-GlcNAc in cardiomyocytes with  
siRNA-mediated knockdown of Nox4, with and without supplementation of GlcNAc (100 μM), or in cells treated with a control siRNA. A represen-
tative immunoblot is shown to the left. To the right are mean data from 4 independent experiments. *P < 0.05, ***P < 0.001, 1-way ANOVA using 
Tukey’s multiple comparison test. (F) IP of CD36 followed by IB for CD36 and O-GlcNAc in membrane fractions from WT and Nox4 TG hearts. A 
representative immunoblot is shown to the left. To the right are mean data from 4 independent experiments. **P < 0.01, ****P < 0.0001, 2-tailed t 
test. See also Supplemental Figure 4.
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Nox4-overexpressing cells was also found in Nox4 TG hearts (Figure 5F). Taken together, these results 
suggest that a putative mechanism by which Nox4 enhances cardiac fatty acid oxidation is as a conse-
quence of  increased O-GlcNAcylation of  CD36.
ATF4 mediates the effects of  Nox4 on the HBP. We next wished to investigate the mechanism through 
which Nox4 increases the activity of  the HBP. Given the build-up of  proximal glycolytic metabolites, it is 
possible that Nox4 may be inhibiting forward flux in the glycolytic pathway with a secondary increase in 
HBP activity. A potential point at which enzyme inhibition may cause such an accumulation of  proximal 
metabolites is GAPDH, which catalyzes the conversion of  glyceraldehyde 3-phosphate to 1,3-bisphos-
phoglycerate (BPG). Interestingly, previous work has shown that GAPDH hyperoxidation inhibits its 
activity (24). We therefore looked for evidence of  GAPDH hyperoxidation in Nox4 TG hearts using an 
antibody against dimedone-conjugated sulfenate (SOH), where hyperoxidation to SO2/SO3 results in 
loss of  the dimedone signal. However, no evidence of  GAPDH hyperoxidation was found (Supplemental 
Figure 5A). Similar experiments in cultured cardiomyocytes overexpressing Nox4 also failed to show 
evidence of  GAPDH hyperoxidation (Supplemental Figure 5B). Furthermore, we found no evidence of  
reduction in GAPDH activity in Nox4 TG compared with WT hearts; in fact, there was a small increase 
in activity (Supplemental Figure 5C).
We then considered the possibility that Nox4 may more directly influence the HBP. The rate-limit-
ing step for UDP-GlcNAc synthesis is the conversion of  fructose 6-phosphate to glucosamine 6-phos-
phate by glutamine fructose-6-phosphate aminotransferase (Gfat). We found that there was a signifi-
cant increase in Gfat1 protein level in unstressed Nox4 TG hearts compared with WT hearts, but there 
was no difference in the levels of  the Gfat2 isoform, while Ogt was slightly increased (Figure 6A). 
Gfat1 and Ogt protein levels increased after banding in the WT group. The overexpression of  Nox4 in 
cultured cardiomyocytes also increased Gfat1 levels without changes in Gfat2 or Ogt (Figure 6B and 
Supplemental Figure 6A). We recently identified a highly specific molecular stress signaling pathway 
through which Nox4 upregulates the transcription factor ATF4 (16). In light of  a recent report that 
Gfat1 is a direct target of  ATF4 (25), we investigated whether Nox4 may influence protein O-Glc-
NAcylation in the heart via an ATF4/Gfat1 pathway. Consistent with this possibility, the hearts of  
Nox4 TG mice demonstrated increased protein levels of  ATF4 as compared with WT hearts, while 
the induction of  pressure overload in WT mice (which increases Nox4 levels; Supplemental Figure 
1A) also increased ATF4 levels (Figure 6C). In cultured cardiomyocytes, treatment with the hypertro-
phic agonist phenylephrine significantly increased the levels of  Nox4, ATF4, and Gfat1, along with 
increasing O-GlcNAcylated proteins (Figure 6D and Supplemental Figure 6B). The siRNA-mediated 
knockdown of  ATF4 substantially inhibited the phenylephrine-induced increase in levels of  Gfat1 and 
protein O-GlcNAcylation (Figure 6E and Supplemental Figure 6C). In turn, the knockdown of  Nox4 
abrogated phenylephrine-induced increases in ATF4 levels and also resulted in an inhibition of  the 
stress-induced increase in Gfat1 and protein O-GlcNAcylation (Figure 6F and Supplemental Figure 
6D). Taken together, these data indicate that the Nox4-induced increase in protein O-GlcNAcylation 
is driven via an ATF4-mediated increase in levels of  the rate-limiting enzyme Gfat1.
Finally, we wanted to assess whether endogenous Nox4 mediates similar ATF4/Gfat1 signaling 
in vivo. We therefore analyzed hearts from Nox4-KO mice and WT littermates subjected to abdom-
inal aortic banding. Whereas WT hearts showed significant increases in the protein levels of  Nox4, 
ATF4, Gfat1, and O-GlcNAcylation after imposition of  chronic pressure overload, these changes were 
substantially inhibited in Nox4-KO hearts (Figure 6G and Supplemental Figure 6E). These results con-
firm that endogenous Nox4 regulates cardiac ATF4/Gfat1/O-GlcNAcylation signaling in response to 
chronic pressure overload in WT mice.
Nox4 TG hearts have preserved cardiac energetics and function. A decrease in fatty acid oxidation in the 
chronically stressed or failing heart is suggested to be an adaptive response (5), but here we report a 
significant increase in fatty acid oxidation in Nox4 TG mouse hearts; however, these animals display a 
beneficial phenotype in the setting of  chronic pressure overload, with less cardiac remodeling and dys-
function (13). We therefore wished to more directly assess the cardiac energetic state in these animals.
We performed cardiac 31P-NMR studies in which Nox4 TG and matched WT hearts from unstressed 
animals or from mice that had been subjected to aortic banding were studied. We also tested the 
response to super-added acute adrenergic stress in all the groups. Nox4 TG and WT hearts had a similar 
basal energetic state, as assessed by the Gibbs free energy or the phosphocreatine/ATP (PCr/ATP) ratio 
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Figure 6. Nox4 regulates Atf4-Gfat1-O-GlcNAc signaling. (A) Protein levels of the HBP enzymes Gfat1, Gfat2, and Ogt in WT and Nox4 TG hearts 
after chronic pressure overload (Band) or control (Sham). Mean data to the right. *P < 0.05, ****P < 0.0001, 2-way ANOVA with Tukey’s post hoc 
correction, n = 3. (B) Effect of overexpression of Nox4 or β-Gal in cultured cardiomyocytes on protein levels of HBP enzymes. Mean data are shown 
in Supplemental Figure 6A. (C) Protein levels of Atf4 in WT and Nox4 TG hearts after aortic banding or sham. Mean data are shown to the right. 
***P < 0.001, 2-way ANOVA with Tukey’s post hoc correction, n = 3. (D) Treatment of cardiomyocytes with phenylephrine (10 μM, 24 h) induced 
an increase in protein levels of Nox4, Atf4, Gfat1, and protein O-GlcNAcylation. (E) Effect of silencing Atf4 on phenylephrine-induced changes in 
Gfat1 and protein O-GlcNAcylation. (F) Effect of silencing Nox4 on phenylephrine-induced changes in Atf4, Gfat1, and protein O-GlcNAcylation. (G) 
Protein levels of the HBP enzymes and Atf4 in WT and Nox4-KO hearts after chronic pressure overload (Band) or control (Sham). Mean data for D–G 
are shown in Supplemental Figure 6.
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(Figure 7, A and B). After an acute challenge with isoproterenol, Nox4 TG hearts had a significantly 
smaller decrease in Gibbs free energy than WT hearts and a higher PCr/ATP ratio (Figure 7, A and B) 
despite a similar workload (Supplemental Figure 7A), indicating a better energetic state. Hypertrophied 
Nox4 TG hearts showed a similar energetic state to WT hypertrophied hearts, both at baseline and after 
acute isoproterenol challenge (Figure 7, C and D, and Supplemental Figure 7B). These results indicate 
that Nox4 TG hearts have well-preserved cardiac energetic and functional states.
Figure 7. Effects of Nox4 on cardiac energetic state. (A–D) Hearts were isolated from Nox4 TG and WT mice under control conditions (A and B) or 
after chronic pressure overload (LVH, C and D) and assessed by 31P-NMR spectroscopy. Energetic state was assessed at baseline (Basal) and after 
acute exposure to isoproterenol (Iso, 50 nM). The Gibbs free energy ([ΔGATP]) and the phosphocreatine/ATP (PCr/ATP) ratio are shown. *P < 0.05 
(WT vs. Nox4 TG), n = 7–8 per group, 2-way ANOVA with Sidak’s multiple comparison’s test. (E) Schematic depicting the effect of increased Nox4 
levels on glucose and fatty acid metabolism. Nox4 augments Atf4/Gfat1 signaling to increase HBP activity and protein O-GlcNAcylation. This, in 
turn, mediates an increase in fatty acid oxidation via an enhancement of CD36 O-GlcNAcylation. This reprogramming of metabolism maintains 
cardiac energetic state and renders the heart more capable of adaptive remodeling.
Downloaded from http://insight.jci.org on January 4, 2018.   https://doi.org/10.1172/jci.insight.96184
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.96184
R E S E A R C H  A R T I C L E
Discussion
Alterations in cardiac metabolism may be a crucial component of  the mechanisms that enable the heart 
to successfully adapt to chronically increased workload while it undergoes hypertrophic remodeling (26). 
However, it remains unclear what changes in metabolic pathways are beneficial in the remodeling heart. 
The Nox family protein Nox4 is significantly upregulated in the heart in response to hemodynamic over-
load and promotes adaptive cardiac remodeling (13). In the present study, we demonstrate that Nox4 
drives significant alterations in cardiac substrate metabolism, including a relative switch from glucose 
oxidation to fatty acid oxidation that maintains energetic status, while promoting adaptive remodeling. 
Nox4 drives an ATF4-mediated increase in activity of  the glycolytic branch pathway, the HBP, which 
facilitates an increase in fatty acid oxidation through O-GlcNAcylation of  the fatty acid transporter CD36 
(Figure 7E). This reprogramming of  cardiac substrate and intermediary metabolism may render the heart 
more capable of  resisting pathological remodeling in the face of  chronic hemodynamic stress. Our results, 
therefore, identify the Nox4/ATF4/HBP axis as a key signaling pathway involved in adaptive metabolic 
reprogramming in the chronically stressed heart.
Fatty acids are the primary source of  energy in the normal well-perfused heart (3). Studies in diverse 
models show that the fatty acid oxidation rate is generally reduced in pathological LVH, while glycolysis is 
increased — but without an equivalent increase in the glucose oxidation rate (2–4). The switch from fatty 
acid to glucose utilization may be part of  the reversion to a fetal phenotype characteristic of  pathological 
LVH and is suggested, in principle, to be beneficial because ATP generation from fatty acids is less oxygen 
efficient than from glucose (3, 27, 28). In addition, the loss of  optimal coupling between glycolysis and glu-
cose oxidation may compromise overall myocardial ATP supply and increase the propensity to intracellular 
acidification. As the heart transitions to overt heart failure, these derangements worsen and coincide with 
a reduced energetic status, leading to the hypothesis that the failing heart is like an engine out of  fuel (29). 
Current therapies in development for heart failure aim to improve energetic status by enhancing glucose 
utilization and the coupling between glycolysis and glucose oxidation (5). A striking finding in the current 
study was that the adaptive remodeling phenotype induced by Nox4 was accompanied by a substantial 
increase in the fatty acid oxidation rate. Furthermore, there was no evidence of  energetic impairment in 
Nox4 TG hearts during acute neurohumoral stress or chronic hemodynamic stress, or during a combina-
tion of  acute and chronic stress. These findings indicate that an increase in fatty acid oxidation per se is not 
necessarily detrimental in the hypertrophied heart but that such an increase may play a central role in the 
maintenance of  energetics in these animals. Our findings are consistent with a number of  other recent stud-
ies that have reported associations between an increase in fatty acid oxidation and preserved LV function 
during hemodynamic overload (30–33). It should be noted, however, that the impact of  increased fatty acid 
oxidation may be different in the setting of  ischemia or diabetes.
The Nox4-driven increase in fatty acid oxidation is integrally linked to a reprogramming of  glucose 
utilization — in particular, a decrease in glucose oxidation and a marked increase in activity of  the HBP as 
assessed by protein O-GlcNAcylation. We found that the Nox4-dependent enhancement of  protein O-Glc-
NAcylation drives the increase in fatty acid oxidation in cells — findings consistent with previous reports 
that an increase in HBP activity enhances cardiac fatty acid oxidation (22). Our studies in isolated cardiac 
mitochondria, as well as the lack of  change in levels of  mitochondrial fatty acid transporters and malonyl 
CoA levels, pointed to a nonmitochondrial mechanism as the basis for the increase in fatty acid oxidation. 
In this regard, an increase in O-GlcNAcylation of  the sarcolemmal fatty acid transporter CD36, which is 
responsible for the majority of  cardiac fatty acid uptake (34), was previously suggested to mediate increased 
fatty acid oxidation in isolated hearts (21, 22). Here, we show that Nox4 drives an increase in O-GlcNAc-
ylation of  CD36, both in cells and in hearts in vivo, which interestingly is accompanied by a modest but 
significant increase in overall levels of  CD36. The Nox4-driven increase in HBP activity and protein O-Glc-
NAcylation, therefore, serves to couple complementary changes in glucose and fatty acid utilization and 
thereby serves to maintain energetic status.
Very little is known about the mechanisms that regulate the HBP in the heart, for example in the 
setting of  hemodynamic overload (20, 35). The enzyme Gfat is considered to be rate limiting for the pro-
duction of  UDP-GlcNAc, which provides the GlcNAc moiety required for protein O-GlcNAcylation. We 
found that Gfat1 levels were significantly increased by Nox4, both in cells and in hearts in vivo, without 
changes in the levels of  Gfat2 or Ogt (which catalyzes the transfer of  O-GlcNAc from UDP-GlcNAc onto 
specific proteins). Gfat1 was recently found to be a direct target of  ATF4 (25), and here, we were able to 
Downloaded from http://insight.jci.org on January 4, 2018.   https://doi.org/10.1172/jci.insight.96184
1 3insight.jci.org   https://doi.org/10.1172/jci.insight.96184
R E S E A R C H  A R T I C L E
demonstrate that the Nox4-dependent upregulation of  Gfat1 was dependent on ATF4. Importantly, our 
studies in Nox4-KO mice — as well as experiments involving the knockdown of  Nox4 in cultured car-
diomyocytes — confirmed that endogenous Nox4 is a crucial physiological regulator of  cardiac ATF4/
Gfat1/O-GlcNAcylation signaling during chronic pressure overload. The increase in Nox4 levels during 
chronic pressure overload is thought to be driven mainly by transcriptional activation, at least in part 
involving neurohumoral agonists (8, 9). How Nox4 upregulates ATF4 in cardiomyocytes was defined in 
detail in our recent work. We identified that Nox4 localized in the ER mediates a targeted redox inhibi-
tion of  protein phosphatase 1 (PP1) in that subcellular compartment, which in turn leads to an increased 
phosphorylation of  the eukaryotic initiation factor eIF2α and an increase in ATF4 translation (16). The 
mechanism is highly specific to endogenous Nox4 and involves both an increase in Nox4 protein level and 
its colocalization with its target (PP1) at the ER (16). An ATF4-driven increase in cytoprotective genes is 
a central mechanism in diverse evolutionarily conserved stress responses (therefore termed the integrated 
stress response) (36, 37). The present findings indicate that it plays an important role in regulating HBP 
activity and adaptive metabolic reprogramming downstream of  Nox4.
Protein O-GlcNAcylation has attracted increasing attention in recent years, with the recognition that it can 
modify the function of numerous cellular proteins both under physiological and pathological conditions (20, 
35). Previous work found that the inhibition of protein O-GlcNAcylation impaired the response to myocardial 
ischemia (38), indicating protective effects of O-GlcNAcylation in this context. On the other hand, increased 
O-GlcNAcylation has also been linked to detrimental effects — for example, in the diabetic heart (35). There 
is as yet very limited knowledge on the mechanisms that determine which protein targets undergo O-Glc-
NAc modification in different physiological or pathophysiological settings and how this impacts on overall 
functional responses. While the protein O-GlcNAcylation of CD36 appears to be an important facet of the 
metabolic reprogramming observed in the present study, further studies are necessary to define the molecular 
mechanism underpinning alteration in CD36 function by O-GlcNAcylation, as well as the precise contribution 
to Nox4-mediated protection during chronic pressure overload. It is likely that the altered O-GlcNAcylation of  
other proteins may also contribute to the overall adaptive remodeling phenotype induced by Nox4. A notable 
feature of the metabolic reprogramming induced by Nox4 was that glucose oxidation was decreased, yet glu-
cose uptake was unaltered. The quantification of glycolytic intermediates demonstrated a relative increase in 
proximal compared with distal intermediates in Nox4 TG hearts. These findings may, at least in part, reflect an 
increase in flux through the HBP. We speculate that, in addition, there may be an increased flux of glucose into 
other glycolytic branch pathways that feed intermediary metabolism (such as the pentose phosphate pathway), 
contributing to the overall beneficial effects of increased Nox4 levels in the heart.
The identification of  mechanisms that enable the heart to successfully adapt to a chronically increased 
workload is central to efforts to develop new therapeutic approaches to prevent and treat chronic heart fail-
ure. In this study, we identify a coordinated reprogramming of  cardiac fatty acid and glucose metabolism 
that is driven by Nox4/HBP/O-GlcNAc signaling as an adaptive pathway in the hemodynamically over-
loaded heart. Our findings indicate that an increase in fatty acid oxidation in this context may be beneficial 
when it occurs as part of  coordinated alterations in glucose and intermediary metabolism, perhaps coupling 
the maintenance of  energetic status to optimal partitioning of  glucose utilization in the remodeling heart.
Methods
Animals. Cardiomyocyte-targeted Nox4 TG mice with a C57BL/6 background and Nox4-KO mice were 
generated as previously described (13). Aortic constriction was performed by suprarenal abdominal 
aortic banding (13).
Proteomics. Two-dimensional DIGE (2D-DIGE) was performed on LV tissue samples labeled with fluo-
rescent cyanine dyes, as previously described (39). Differentially expressed protein spots were excised, digest-
ed with trypsin, and analyzed by liquid chromatography tandem MS (LC-MS/MS) on an LTQ Orbitap XL 
mass spectrometer (Thermo Fisher Scientific) (39). Spectra were searched against a mouse database (Swis-
sProt) using the SEQUEST algorithm (SRF v5) and analyzed by Scaffold software (v2.1.03). The enriched 
GO biological functions were analyzed using the Reactome database (http://www.reactome.org/). Detailed 
methods are described in the Supplemental Methods.
Reverse transcription PCR (RT-PCR), immunoblotting, and immunoprecipitation studies. Real-time PCR was 
performed using Sybr Green (Applied Biosystems) and the ΔΔCt method. IB was performed using stan-
dard methods, with quantification by enhanced chemiluminescence and densitometry. We used a CD36 
Downloaded from http://insight.jci.org on January 4, 2018.   https://doi.org/10.1172/jci.insight.96184
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.96184
R E S E A R C H  A R T I C L E
antibody (Abcam) coupled to protein A/G agarose for IP. Detailed methods including primer sequences 
and antibody sources are described in the Supplemental Methods.
Isolated heart substrate utilization. Myocardial substrate utilization was quantified in isolated ejecting 
heart preparations perfused with a mixture of  substrates (including glucose and palmitate), as previously 
described (18). The use of  14C-labeled glucose or palmitate and 3H-labeled glucose enabled the assessment 
of  glucose or fatty acid oxidation, glucose uptake, and glycolytic flux (Figure 2, A–D). Metabolic rates were 
normalized by the dry heart weight. Full details are provided in the Supplemental Methods.
Measurement of  glycolytic metabolites by LC-MS. Metabolites were isolated from flash-frozen hearts using 
a modified Bligh-Dyer methanol/chloroform method (40). Compounds were separated by liquid-chroma-
tography using a Waters Acquity Ultra Performance Liquid Chromatography unit (Waters Ltd.) and ana-
lyzed in negative and positive ion mode in a Sciex 5500 triple quadrupole mass spectrometer (AB Sciex). 
Full details are provided in the Supplemental Methods.
Cells and transfections. Neonatal rat cardiomyocytes were isolated and cultured using standard meth-
ods (13). Adenoviral vectors for the overexpression of  Nox4 (Ad.Nox4), knockdown of  Nox4 with 
a short hairpin sequence (Ad.shNox4), and respective controls (Ad.βGal, Ad.Ctl), as well as siRNA 
sequences for the knockdown of  ATF4, were previously described (16). Full details are provided in the 
Supplemental Methods.
Extracellular flux assays. Neonatal rat cardiomyocytes were isolated and cultured onto gelatin-coated 
Seahorse XFe24 well-plates. Oxygen consumption rates (OCR) and ECAR were measured according to the 
manufacturer’s protocol. Full details are provided in the Supplemental Methods.
31P NMR spectroscopy in isolated hearts. Hearts were perfused in isovolumic Langendorff  mode with mod-
ified Krebs-Henseleit buffer containing glucose and octanoate. 31P NMR spectroscopy was performed using 
a Bruker Avance III 400 MHz spectrometer (41). Quantification of  Pi, PCr, and β-ATP (mM) and the cal-
culation of  intracellular pH and ΔGATP were performed using established methods (42, 43). Full details are 
provided in the Supplemental Methods.
Other biochemical assays. The respiration of  isolated mitochondria was measured using a high-resolution 
respirometer (OROBOROS Oxygraph-2K). Cardiac mitochondria were isolated (44) and OCR measured 
for multiple substrates. PDH enzymatic activity was measured in mitochondrial fractions using a com-
mercially available dipstick assay (ab109882, Abcam) and normalized to the relative amount of  PDH E1α 
protein. GAPDH activity was measured in heart tissue lysate using a commercially available colorimetric 
assay (ab204732, Abcam). Detailed protocols are described in the Supplemental Methods.
Statistics. Data are shown as the mean ± SEM. Differences in means were compared by unpaired, 2-tailed 
Student’s t tests, 1-way ANOVA or 2-way ANOVA, followed by a post-hoc test for multiple comparisons, as 
appropriate. Analyses were performed using GraphPad Prism (v6.0). P < 0.05 was considered significant.
Study approval. All procedures were performed in accordance with the Guidance on the Operation of  
the Animals (Scientific Procedures) Act, 1986 (United Kingdom), and/or EU Directive 2010/63 on the use 
of  animals for scientific purposes and were approved by ethical review panels at King’s College London 
and the Arctic University of  Norway.
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